Prevagen
This article was originally published in The Tan Sheet
Executive Summary
A dietary supplement consisting of jellyfish protein aequorin and claiming "anti-aging activity" in University of Wisconsin-Milwaukee lab studies should be in stores by Sept. 1, 2007, Prevagen developer Quincy Bioscience announced at the Expo West tradeshow in Anaheim, Calif. March 23. The product acts as a calcium-binding protein, replacing those that are depleted "in several areas of the body as part of the aging process," according to the Madison, Wis.-based firm. Prevagen can be "be marketed as a dietary supplement and in the future go through clinical trials with the goal of getting FDA approval towards neurodegenerative disease," the company notes...